No Prescription |
 |
 | ||
|
Viraday Atripla |
|
| ||
No Prescription » Prescription Drugs 17 » Viraday Atripla This drug contains 3 different medications (efavirenz emtricitabine tenofovir) and is used alone or in combination with other medications. It helps to control your HIV infection thereby improving your quality of life. It also lowers your risk of getting HIV complications (e.g. new infections cancer). Efavirenz/emtricitabine/tenofovir combination contains 2 different classes of anti-HIV medicines which are known as nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors.Efavirenz/emtricitabine/tenofovir is not a cure for HIV infection and it does not prevent the spread of HIV to others through sexual contact or blood contamination (e.g. sharing used needles).How to use Viraday OralRead the Patient Information Leaflet provided by your pharmacist before you start using efavirenz/emtricitabine/tenofovir and each time you get a refill. If you have any questions consult your doctor or pharmacist.Take this medication by mouth without food usually once daily or as directed by your doctor. To decrease some of the side effects (drowsiness dizziness) take your dose at bedtime.Dosage is based on your medical condition and response to therapy.Because this combination product has fixed doses of efavirenz emtricitabine and tenofovir it should only be used if your doctor has determined that the doses of all 3 medications in this product are right for you.It is very important to continue taking this medication (and other HIV medications) exactly as prescribed by your doctor.This medication works best when the amount of drug in your body is kept at a constant level. Therefore take this drug at evenly spaced intervals. To help you remember take it at the same time each day.Do not take more or less of this drug than prescribed or stop taking it (or other HIV medicines) even for a short time unless directed to do so by your doctor. Skipping or changing your dose without approval from your doctor may cause the amount of virus to increase make the infection more difficult to treat (resistant) or worsen side effects. Do not run out of this medication. Order your refills several days early to avoid running out of pills.Inform your doctor if your condition persists or worsens (e.g. new fevers weight loss increased tiredness persistent diarrhea white patches in your mouth or on your tongue).Viraday Oral is used to treat the following:HIV Buy Viraday Atripla and other Prescription Drugs 17 products online at Medstore. Buy Online at Medstore - Click Here!
About Viraday Atripla: Product Type: Prescription Drugs 17 Viraday ( Atripla Generic Efavirenz/Emtricitabine/Tenofovir ) Viraday (Atripla Generic Efavirenz/Emtricitabine/Tenofovir) Atripla Generic Efavirenz/Emtricitabine/Tenofovir 600/200/300mg Atripla Generic Efavirenz/Emtricitabine/Tenofovir Viraday
View more Prescription Drugs 17 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
